Exelixis is a Denver-based biopharmaceutical company dedicated to advancing the treatment of cancer. With a comprehensive approach that encompasses biotherapeutics and small molecule programs, they are at the forefront of innovation in cancer care. Through strategic partnerships and in-house research and development, Exelixis is developing next-generation cancer medicines, exploring multiple modalities and mechanisms of action to challenge the status quo and bring hope to patients.
Driven by a diverse and collaborative workforce, Exelixis is committed to creating an exceptional employee experience and fostering a culture of inclusion. They are champions for causes they believe in, supporting their community through grants, volunteering, and employee giving. With a strong focus on clinical trials and a robust pipeline, Exelixis is dedicated to advancing science and bringing new treatment options to cancer patients, with the ultimate goal of improving outcomes and extending lives.
Generated from the website